Hot pre-market trades in US stocks: Sellas up 7.95% pre-market, receives $56 million partnership funding from Jazz
I'm LongbridgeAI, I can summarize articles.Sellas Life Sciences pre-market up 7.95%; Nature's Way pre-market up 162.12%; Decoy Therapeutics pre-market up 126.53%; Inlif pre-market up 47.97%
Pre-market Hot Trades in US Stocks
Sellas is up 7.95% in pre-market trading. Based on recent key news:
-
On June 29, Sellas reached a collaboration agreement with Jazz Pharmaceuticals, focusing on the research of multispecific T cell-engaging antibodies. The agreement includes $56 million in upfront funding, driving the stock price up.
-
On June 26, Sellas's stock price rose 17.56% on Thursday, as its product line includes peptide immunotherapies targeting the WT1 antigen and selective small molecule CDK9 inhibitors, attracting investor attention.
-
On June 26, analysts rated Sellas as "Buy" or higher, with a 12-month average target price of $10, indicating about 9% potential upside. The biotechnology sector has performed strongly recently, with significant capital inflows.
Top Gainers in Pre-market US Stocks
Nature's Way is up 162.12% in pre-market trading. Based on recent key news:
-
On June 26, Nature's Way announced the acquisition of Best Praise International Limited for $10.75 million, to be paid in 4,376,552 shares of common stock. This move aims to expand its pharmaceutical patent portfolio and is expected to have a positive impact on the company's future development. Source: Reuters
-
On June 26, Best Praise holds five Chinese patents related to drug development, covering age-related diseases, cognitive and neurodegenerative diseases, and drug delivery technologies. These patents are considered complementary to Nature's Way's existing business and may provide additional R&D and commercialization opportunities. Source: WSJ
-
On June 26, the transaction is expected to be completed in the third quarter of 2026, further consolidating Nature's Way's position in the Chinese market. Source: Company News The pharmaceutical industry has recently seen significant impacts from policy changes.
Decoy Therapeutics is up 126.53% in pre-market trading. Based on recent key news:
-
On June 26, Decoy Therapeutics announced a private placement financing of up to $21 million. This news boosted market confidence in the company's future development, significantly driving up the stock price.
-
On June 26, Decoy Therapeutics launched its innovative product Designable Multi-Antivirals (D-MAVs™) in Houston, a unique antiviral drug designed to target common viral mechanisms across multiple virus families. The product launch further enhanced investor recognition of the company's technological strength, leading to a stock price increase.
-
On June 29, Decoy Therapeutics signed a lock-up agreement with Curvature Securities to support orderly trading post-financing. The signing of this agreement ensures market stability after financing, further driving up the stock price The biotechnology industry has shown strong performance recently, with significant capital inflows.
Inlif rose 47.97% in pre-market trading. Based on recent key news:
- On June 26, TipRanks' AI analyst Spark rated Inlif stock as neutral, with a target price of $0.05. Spark pointed out that the financial performance is expected to deteriorate sharply in 2025 (loss results and negative cash flow), and the technical indicators are very weak (severely oversold momentum and prices far below major moving averages), which has led to stock price volatility.
Recent market fluctuations are significant, and attention should be paid to macroeconomic dynamics